UBS Sticks to Its Buy Rating for UnitedHealth (UNH)
In a report released today, A.J. Rice from UBS maintained a Buy rating on UnitedHealth, with a price target of $410.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Rice is a 5-star analyst with an average return of 7.8% and a 58.75% success rate. Rice covers the Healthcare sector, focusing on stocks such as HCA Healthcare, Acadia Healthcare, and Humana.
In addition to UBS, UnitedHealth also received a Buy from Morgan Stanley’s Erin Wright in a report issued today. However, yesterday, TD Cowen assigned a Hold rating to UnitedHealth (NYSE: UNH).
Based on UnitedHealth’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $113.22 billion and a net profit of $10 million. In comparison, last year the company earned a revenue of $100.81 billion and had a net profit of $5.54 billion
Read More on UNH:
Disclaimer & DisclosureReport an Issue
- UnitedHealth elevated to Top Pick at Morgan Stanley
- UnitedHealth faces challenges as government preps overhaul, WSJ says
- UNH Stock Earnings Preview: What to Expect from UnitedHealth’s Q1 Results
- Morgan Stanley Names UnitedHealth Stock (UNH) a Top Pick ahead of Q1 Earnings – Here’s Why
- One in seven enrollees in ACA plans failed to make payments this year, WSJ says
